NASDAQ · MLTX
Healthcare · Biotechnology
$11.70
Down-$0.32 (-2.72%)
Updated Nov 4, 2026, 7:04 PM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MLTX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
MLTX closed at $11.70 after 21 trading sessions, up 6.85% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $11.52 | $11.72 | $11.29 | $11.70 | 856.02K |
| Nov 2, 2026 | $11.80 | $11.995 | $11.17 | $11.47 | 972.02K |
| Oct 30, 2026 | $12.44 | $12.6296 | $11.71 | $11.78 | 1.13M |
| Oct 29, 2026 | $12.36 | $12.95 | $12.31 | $12.57 | 4.1M |
| Oct 28, 2026 | $11.87 | $12.38 | $11.71 | $12.31 | 1.21M |
| Oct 27, 2026 | $11.77 | $12.10 | $11.54 | $11.93 | 934.42K |
| Oct 26, 2026 | $11.77 | $12.46 | $11.665 | $11.81 | 1.51M |
| Oct 23, 2026 | $12.07 | $12.28 | $11.48 | $11.85 | 1.94M |
| Oct 22, 2026 | $10.70 | $13.334 | $10.65 | $12.34 | 6.12M |
| Oct 21, 2026 | $10.34 | $10.73 | $10.34 | $10.65 | 1.16M |
| Oct 20, 2026 | $9.77 | $10.48 | $9.731 | $10.32 | 1.24M |
| Oct 19, 2026 | $9.57 | $9.8625 | $9.50 | $9.75 | 911.74K |
| Oct 16, 2026 | $10.34 | $10.34 | $9.46 | $9.55 | 1.38M |
| Oct 15, 2026 | $10.16 | $10.505 | $10.1354 | $10.26 | 1.07M |
| Oct 14, 2026 | $10.30 | $10.65 | $10.005 | $10.14 | 1.77M |
| Oct 13, 2026 | $10.70 | $10.84 | $10.355 | $10.41 | 2.41M |
| Oct 12, 2026 | $10.82 | $11.00 | $10.66 | $10.68 | 1.21M |
| Oct 9, 2026 | $10.58 | $11.09 | $10.40 | $10.82 | 2.01M |
| Oct 8, 2026 | $10.75 | $10.795 | $10.00 | $10.58 | 3.72M |
| Oct 7, 2026 | $10.81 | $11.29 | $10.71 | $10.77 | 1.4M |
| Oct 6, 2026 | $11.50 | $11.50 | $10.91 | $10.95 | 3.05M |
The latest Smart Investors Daily articles mentioning MLTX.
Company
Market Activity
Research & News
MLTX research
Company profile and research snapshot.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 5, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 20, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 1, 2026 | Leerink Partners | Outperform | — |
| Jun 9, 2026 | BTIG | Buy | — |
Generated Nov 4, 2026, 7:00 PM
MoonLake Immunotherapeutics shares declined 2.48% today following the release of third-quarter earnings results that significantly missed analyst expectations. The company reported an EPS of $(0.93), substantially worse than the estimated $(0.78), signaling deeper operational losses and raising questions about the company's path to profitability.
Bottom line: MLTX's 2.48% decline reflects investor disappointment with Q3 results that significantly overshot loss expectations, signaling either operational inefficiencies or accelerated spending that wasn't priced into analyst models. For investors, the key question is whether this miss represents a temporary setback or a warning sign about unsustainable cash burn; monitoring upcoming pipeline updates, clinical trial progress, and management guidance on capital runway will be critical to reassessing the risk/reward proposition.
Benzinga · Nov 4, 2026
MoonLake (NASDAQ:MLTX) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.78) by 19.23 percent. This is a 15.45 percent increase over losses of $(1.10) per share from the
Yahoo · Oct 25, 2026
Recent Performance Snapshot MoonLake Immunotherapeutics (MLTX) has drawn fresh attention after recent trading saw the share price close at $11.85. Performance has been mixed across timeframes and marked by sharp moves over the past 3 months. That recent jump in MoonLake Immunotherapeutics, with a 7-day share price return of 24.08%, comes after a much weaker 90-day share price move that declined 40.39%. Meanwhile, the 1-year total shareholder return of 24.47% contrasts sharply with a 3-year...
Yahoo · Oct 25, 2026
MoonLake Immunotherapeutics has seen sharp swings in its share price in recent years, which puts fresh focus on what investors are really paying for on the balance sheet. With the stock last closing at US$11.85, the live question is how that market tag lines up with the company’s book value. The share price has fallen 76.3% over the past 3 years. This long term slide raises a direct question about how much equity value MoonLake Immunotherapeutics is now being credited with. For a clinical...
Yahoo · Oct 22, 2026
Key TakeawaysAbbVie’s lutikizumab met its Phase 3 goal in hidradenitis suppurativa, with 31. 4% of patients reaching HiSCR75 at Week 16 versus 23.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MLTX.
